Valuations (3)

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A private biotech company was preparing for an IPO. The company was developing a first-in-class small molecule inhibitor with the potential to treat a range of tumor types. The company was...

Challenge A biotech company engaged in licensing discussions with a number of major pharma companies needed help with risk adjusted NPV (rNPV) valuations for each program.

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.

Challenge A virtual life science company had raised money from angel investors and anticipated a clinical development strategy for their product targeting two major cancer indications. The client...

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...

Challenge A biotech company needed support with an active partnering process with several major pharma companies.

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...

Oncology company with a preclinical project seeking finance and potential acquisition For a virtual life science company, Alacrita helped establish a valuation trajectory for one of their products,...

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD...

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...